Gilead Sciences, Inc.GILDNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +6.40% | -0.28% | +1.84% | +2.97% | +4.70% |
| Gross Profit Growth | +19.19% | -0.14% | +3.16% | +3.84% | +14.93% |
| EBITDA Growth | +19.90% | +0.00% | +13.07% | +143.26% | -24.96% |
| Operating Income Growth | +52.11% | +0.00% | -6.43% | +274.66% | +20.88% |
| Net Income Growth | +24.77% | +0.00% | +21.44% | +143.58% | +22.43% |
| EPS Growth | +24.35% | +0.00% | +21.71% | +146.00% | +23.08% |
| EPS Diluted Growth | +24.56% | +0.00% | +20.93% | +143.00% | +22.54% |
| Weighted Average Shares Growth | +0.00% | -0.08% | -0.16% | -0.32% | -0.48% |
| Weighted Average Shares Diluted Growth | +0.24% | +0.96% | +0.32% | +0.00% | -0.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +37.16% | -20.82% | -37.58% | -4.66% | +11.80% |
| Free Cash Flow Growth | +44.73% | -21.81% | -39.75% | -4.97% | +10.36% |
| Receivables Growth | -5.15% | -6.02% | +2.53% | +11.07% | +11.15% |
| Inventory Growth | -4.31% | -5.07% | -9.92% | -4.49% | +155.44% |
| Asset Growth | -5.04% | +0.25% | +4.00% | +7.35% | +0.05% |
| Book Value per Share Growth | -15.34% | +9.34% | +7.80% | +16.97% | +17.58% |
| Debt Growth | +6.49% | -0.96% | +6.84% | +7.28% | -9.99% |
| R&D Expense Growth | +16.55% | -9.28% | +10.36% | -3.51% | -4.63% |
| SG&A Expenses Growth | +17.78% | -8.51% | -0.87% | -3.76% | -4.51% |